China Biologic Products (NASDAQ:CBPO) Raised to Sell at BidaskClub

BidaskClub upgraded shares of China Biologic Products (NASDAQ:CBPO) from a strong sell rating to a sell rating in a research note released on Thursday, March 15th.

Several other research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of China Biologic Products from a hold rating to a sell rating in a research report on Monday, March 5th. TheStreet downgraded shares of China Biologic Products from a b- rating to a c+ rating in a research report on Thursday, March 1st. Finally, Deutsche Bank set a $105.00 price target on shares of China Biologic Products and gave the stock a buy rating in a research report on Friday, March 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $101.00.

How to Become a New Pot Stock Millionaire

China Biologic Products stock traded up $0.02 during midday trading on Thursday, reaching $84.78. 140,193 shares of the company traded hands, compared to its average volume of 231,189. The company has a market cap of $2,808.34, a price-to-earnings ratio of 17.13, a price-to-earnings-growth ratio of 1.29 and a beta of 1.46. China Biologic Products has a 12 month low of $71.85 and a 12 month high of $120.46.

China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.90 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.01. The company had revenue of $90.10 million for the quarter, compared to the consensus estimate of $85.15 million. China Biologic Products had a net margin of 18.34% and a return on equity of 21.30%. The firm’s revenue for the quarter was up 16.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.95 earnings per share. equities research analysts predict that China Biologic Products will post 5.22 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Schroder Investment Management Group raised its position in shares of China Biologic Products by 86.5% during the 3rd quarter. Schroder Investment Management Group now owns 1,016,092 shares of the biopharmaceutical company’s stock valued at $92,799,000 after purchasing an additional 471,416 shares during the period. Bank of New York Mellon Corp raised its position in shares of China Biologic Products by 5.5% during the 4th quarter. Bank of New York Mellon Corp now owns 804,495 shares of the biopharmaceutical company’s stock valued at $63,370,000 after purchasing an additional 41,711 shares during the period. Artisan Partners Limited Partnership raised its position in shares of China Biologic Products by 62.9% during the 3rd quarter. Artisan Partners Limited Partnership now owns 723,859 shares of the biopharmaceutical company’s stock valued at $66,790,000 after purchasing an additional 279,420 shares during the period. Comgest Global Investors S.A.S. raised its position in shares of China Biologic Products by 78.5% during the 4th quarter. Comgest Global Investors S.A.S. now owns 635,752 shares of the biopharmaceutical company’s stock valued at $50,078,000 after purchasing an additional 279,500 shares during the period. Finally, Macquarie Group Ltd. raised its position in shares of China Biologic Products by 2.3% during the 3rd quarter. Macquarie Group Ltd. now owns 601,087 shares of the biopharmaceutical company’s stock valued at $55,462,000 after purchasing an additional 13,500 shares during the period. Hedge funds and other institutional investors own 56.27% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/04/08/china-biologic-products-cbpo-upgraded-to-sell-by-bidaskclub.html.

About China Biologic Products

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply